NCT06466486View on ClinicalTrials.gov

An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian Stimulation

PHASE1TerminatedINTERVENTIONAL
Enrollment

310

Participants

Timeline

Start Date

June 14, 2024

Primary Completion Date

September 5, 2025

Study Completion Date

September 5, 2025

Conditions
Fertility
Interventions
DRUG

Follitropin delta

The effect on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin.

DRUG

FE999302

To investigate the effect of FE 999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol

DRUG

FE999302 Placebo

To investigate the effect of FE 999302 on parameters influencing pregnancy rates in women undergoing controlled ovarian stimulation with a fixed dose of follitropin delta in a gonadotropin-releasing hormone (GnRH) antagonist protocol

Trial Locations (15)

1090

Ferring Investigational Site, Brussels

2100

Ferring Investigational Site, Copenhagen

2650

Ferring Investigational Site, Edegem

Ferring Investigational Site, Hvidovre

3913

Ferring Investigational Site, Porsgrunn

5006

Ferring Investigational Site, Bergen

7042

Ferring Investigational Site, Trondheim

28010

Ferring Investigational Site, Madrid

28023

Ferring Investigational Site, Madrid

41092

Ferring Investigational Site, Seville

46015

Ferring Investigational Site, Valencia

150 00

Ferring Investigational Site, Prague

160 00

Ferring Investigational Site, Prague

184 00

Ferring Investigational Site, Prague

08028

Ferring Investigational Site, Barcelona

Sponsors
All Listed Sponsors
lead

Ferring Pharmaceuticals

INDUSTRY

NCT06466486 - An Exploratory Study to Investigate the Effect of FE 999302 When Given Together With Follitropin Delta During Controlled Ovarian Stimulation | Biotech Hunter | Biotech Hunter